anurajms/meta_analysis huggingface dataset:
MESH terms:
Occupational therapy for adults with problems in activities of daily living after stroke
1. *Activities of Daily Living; 2. Depression [epidemiology]; 3. *Occupational Therapy; 4. Randomized Controlled Trials as Topic; 5. Stroke [mortality, psychology]; 6. *Stroke Rehabilitation;
MESH terms:
Early supported discharge services for people with acute stroke
1. *Length of Stay; 2. *Patient Discharge [economics]; 3. *Stroke Rehabilitation; 4. Cost‐Benefit Analysis; 5. Home Care Services, Hospital‐Based [economics, *organization & administration]; 6. Home Nursing [economics, organization & administration]; 7. Patient Readmission [statistics & numerical data]; 8. Randomized Controlled Trials as Topic; 9. Stroke [economics, mortality];
MESH terms:
Psychological interventions for acute pain after open heart surgery
1. Acute Pain [psychology, *therapy]; 2. Analgesics [therapeutic use]; 3. Behavior Therapy [*methods]; 4. Cardiac Surgical Procedures [*adverse effects]; 5. Cognitive Behavioral Therapy; 6. Pain Measurement; 7. Pain, Postoperative [psychology, *therapy]; 8. Randomized Controlled Trials as Topic; 9. Relaxation Therapy [*methods]; 10. Stress, Psychological [epidemiology];
MESH terms:
Niacin for primary and secondary prevention of cardiovascular events
1. *Primary Prevention; 2. *Secondary Prevention; 3. Cardiovascular Diseases [mortality, *prevention & control]; 4. Myocardial Infarction [mortality, prevention & control]; 5. Niacin [*administration & dosage, adverse effects]; 6. Randomized Controlled Trials as Topic [statistics & numerical data]; 7. Stroke [mortality, prevention & control]; 8. Vasodilator Agents [*administration & dosage, adverse effects];
MESH terms:
Growth factors for angiogenesis in peripheral arterial disease
1. Amputation, Surgical [statistics & numerical data]; 2. Fibroblast Growth Factors [adverse effects, *therapeutic use]; 3. Hepatocyte Growth Factor [adverse effects, *therapeutic use]; 4. Intermittent Claudication [*drug therapy, mortality]; 5. Leg [blood supply, surgery]; 6. Leg Ulcer [drug therapy]; 7. Peripheral Arterial Disease [*drug therapy, mortality]; 8. Randomized Controlled Trials as Topic; 9. Vascular Endothelial Growth Factor A [adverse effects, *therapeutic use];
MESH terms:
Circuit class therapy for improving mobility after stroke
1. *Walking Speed; 2. Arm [physiology]; 3. Exercise Therapy [adverse effects, *methods]; 4. Gait [physiology]; 5. Postural Balance [physiology]; 6. Randomized Controlled Trials as Topic; 7. Recovery of Function; 8. Stroke Rehabilitation [*methods]; 9. Walk Test;
MESH terms:
Laparoscopic surgery for elective abdominal aortic aneurysm repair
1. Aortic Aneurysm, Abdominal [*surgery]; 2. Elective Surgical Procedures [adverse effects, *methods]; 3. Endovascular Procedures [adverse effects, *methods]; 4. Laparoscopy [adverse effects, *methods]; 5. Length of Stay; 6. Operative Time; 7. Randomized Controlled Trials as Topic;
MESH terms:
Complete versus culprit‐only revascularisation in ST elevation myocardial infarction with multi‐vessel disease
1. Cause of Death; 2. Coronary Stenosis [complications, mortality, *surgery]; 3. Myocardial Revascularization [adverse effects, *methods, mortality]; 4. Randomized Controlled Trials as Topic; 5. ST Elevation Myocardial Infarction [etiology, mortality, *surgery];
MESH terms:
Nitric oxide donors (nitrates), L‐arginine, or nitric oxide synthase inhibitors for acute stroke
1. Acute Disease; 2. Arginine [*therapeutic use]; 3. Brain Ischemia [drug therapy]; 4. Enzyme Inhibitors [*therapeutic use]; 5. Headache [chemically induced]; 6. Nitric Oxide Donors [adverse effects, *therapeutic use]; 7. Nitric Oxide Synthase [*antagonists & inhibitors]; 8. Nitroglycerin [adverse effects, *therapeutic use]; 9. Quality of Life; 10. Randomized Controlled Trials as Topic; 11. Stroke [*drug therapy, mortality];
MESH terms:
Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation
1. Administration, Oral; 2. Anticoagulants [*administration & dosage, adverse effects]; 3. Anxiety [prevention & control]; 4. Atrial Fibrillation [blood, *complications]; 5. Chronic Disease; 6. Decision Support Techniques; 7. Drug Monitoring [*methods, standards]; 8. *International Normalized Ratio [standards]; 9. Medication Adherence; 10. *Patient Education as Topic; 11. Randomized Controlled Trials as Topic; 12. Self Care [methods]; 13. Stroke [blood, etiology, *prevention & control];
MESH terms:
Blood pressure lowering efficacy of renin inhibitors for primary hypertension
1. Amides [administration & dosage, adverse effects, *therapeutic use]; 2. Antihypertensive Agents [administration & dosage, adverse effects, *therapeutic use]; 3. Blood Pressure [*drug effects]; 4. Diarrhea [chemically induced]; 5. Fumarates [administration & dosage, adverse effects, *therapeutic use]; 6. Randomized Controlled Trials as Topic; 7. Renin [*antagonists & inhibitors];
MESH terms:
Low‐molecular‐weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
1. Acute Disease; 2. Anticoagulants [*therapeutic use]; 3. Brain Ischemia [drug therapy]; 4. Cause of Death; 5. Fibrinolytic Agents [*therapeutic use]; 6. Hemorrhage [chemically induced, epidemiology]; 7. Heparin [therapeutic use]; 8. Heparin, Low‐Molecular‐Weight [*therapeutic use]; 9. Heparinoids [*therapeutic use]; 10. Pulmonary Embolism [epidemiology]; 11. Randomized Controlled Trials as Topic; 12. Stroke [*drug therapy, mortality]; 13. Venous Thrombosis [epidemiology];
MESH terms:
Exercise‐based cardiac rehabilitation in heart transplant recipients
1. *Exercise; 2. *Exercise Tolerance; 3. Cardiac Rehabilitation [*methods]; 4. Heart Transplantation [*rehabilitation]; 5. High‐Intensity Interval Training; 6. Physical Conditioning, Human [*methods]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic;
MESH terms:
Continuous chest compression versus interrupted chest compression for cardiopulmonary resuscitation of non‐asphyxial out‐of‐hospital cardiac arrest
1. Blood Circulation [physiology]; 2. Cardiopulmonary Resuscitation [*methods, mortality]; 3. Emergency Medical Technicians; 4. Heart Massage [*methods]; 5. Hospitalization; 6. Out-of-Hospital Cardiac Arrest [classification, etiology, mortality, *therapy]; 7. Randomized Controlled Trials as Topic; 8. Telephone; 9. Thorax; 10. Treatment Outcome;
MESH terms:
Vitamin C supplementation for the primary prevention of cardiovascular disease
1. Angioplasty, Balloon, Coronary [statistics & numerical data]; 2. Ascorbic Acid [*administration & dosage]; 3. Cardiovascular Diseases [epidemiology, *prevention & control]; 4. Coronary Artery Bypass [statistics & numerical data]; 5. *Dietary Supplements; 6. Myocardial Infarction [epidemiology]; 7. Physicians; 8. Primary Prevention [*methods]; 9. Publication Bias; 10. Randomized Controlled Trials as Topic; 11. Stroke [epidemiology]; 12. Vitamins [*administration & dosage];
MESH terms:
Risk scoring for the primary prevention of cardiovascular disease
1. Anticholesteremic Agents [therapeutic use]; 2. Antihypertensive Agents [therapeutic use]; 3. Blood Pressure; 4. Cardiovascular Diseases [blood, etiology, *prevention & control]; 5. Cholesterol [blood]; 6. Heart Diseases [prevention & control]; 7. Primary Prevention [*methods]; 8. Randomized Controlled Trials as Topic; 9. Risk Assessment; 10. Risk Factors; 11. Stroke [prevention & control];
MESH terms:
Fixed‐dose combination therapy for the prevention of atherosclerotic cardiovascular diseases
1. Anticholesteremic Agents [*administration & dosage, adverse effects]; 2. Antihypertensive Agents [*administration & dosage, adverse effects]; 3. Aspirin [*administration & dosage, adverse effects]; 4. Blood Pressure [drug effects]; 5. Cardiovascular Diseases [mortality, *prevention & control]; 6. Cause of Death; 7. Cholesterol [blood]; 8. Drug Combinations; 9. Placebo Effect; 10. Platelet Aggregation Inhibitors [*administration & dosage, adverse effects]; 11. Randomized Controlled Trials as Topic;
MESH terms:
Eplerenone for hypertension
1. Antihypertensive Agents [*administration & dosage, adverse effects]; 2. Blood Pressure [drug effects]; 3. Eplerenone; 4. Essential Hypertension; 5. Hypertension [complications, *drug therapy]; 6. Patient Dropouts [statistics & numerical data]; 7. Randomized Controlled Trials as Topic; 8. Spironolactone [administration & dosage, adverse effects, *analogs & derivatives];
MESH terms:
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism
1. Anticoagulants [*administration & dosage, adverse effects]; 2. Hemorrhage [chemically induced]; 3. Heparin [administration & dosage, adverse effects]; 4. Heparin, Low‐Molecular‐Weight [*administration & dosage, adverse effects]; 5. Injections, Subcutaneous; 6. Pulmonary Embolism [*drug therapy, mortality]; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Venous Thrombosis [*drug therapy, mortality];
MESH terms:
Ranolazine for stable angina pectoris
1. Angina, Stable [*drug therapy, mortality, prevention & control]; 2. Cardiovascular Agents [administration & dosage, adverse effects, *therapeutic use]; 3. Cause of Death; 4. Incidence; 5. Myocardial Infarction [epidemiology]; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Ranolazine [administration & dosage, adverse effects, *therapeutic use];
MESH terms:
Beta‐blockers for hypertension
1. Adrenergic beta‐Antagonists [adverse effects, *therapeutic use]; 2. Angiotensin Receptor Antagonists [therapeutic use]; 3. Antihypertensive Agents [adverse effects, *therapeutic use]; 4. Atenolol [therapeutic use]; 5. Calcium Channel Blockers [therapeutic use]; 6. Coronary Disease [prevention & control]; 7. Diuretics [therapeutic use]; 8. Heart Arrest [prevention & control]; 9. Hypertension [*drug therapy, mortality]; 10. Randomized Controlled Trials as Topic; 11. Stroke [prevention & control];
MESH terms:
Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm
1. Antihypertensive Agents [therapeutic use]; 2. Aortic Aneurysm, Abdominal [*complications, mortality]; 3. Cardiovascular Agents [*therapeutic use]; 4. Cardiovascular Diseases [mortality, *prevention & control]; 5. Cause of Death; 6. Metoprolol [*therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Risk Factors;
MESH terms:
Stem cell therapy for chronic ischaemic heart disease and congestive heart failure
1. Adult Stem Cells [transplantation]; 2. Arrhythmias, Cardiac [epidemiology]; 3. Bone Marrow Cells [cytology]; 4. Chronic Disease; 5. Heart Failure [mortality, *surgery]; 6. Hospitalization [statistics & numerical data]; 7. Myocardial Infarction [epidemiology]; 8. Myocardial Ischemia [mortality, *surgery]; 9. Patient Readmission; 10. Randomized Controlled Trials as Topic; 11. Stem Cell Transplantation [adverse effects, *methods, mortality]; 12. Stroke Volume [physiology];
MESH terms:
Caregiver‐mediated exercises for improving outcomes after stroke
1. *Caregivers; 2. *Postural Balance; 3. *Quality of Life; 4. Activities of Daily Living; 5. Exercise Therapy [*methods]; 6. Randomized Controlled Trials as Topic; 7. Stroke Rehabilitation [*methods]; 8. Walking;
MESH terms:
Blood pressure‐lowering efficacy of reserpine for primary hypertension
1. Antihypertensive Agents [administration & dosage, *therapeutic use]; 2. Blood Pressure [*drug effects]; 3. Heart Rate [drug effects]; 4. Hypertension [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Rauwolfia [chemistry]; 7. Reserpine [administration & dosage, *therapeutic use];
MESH terms:
Interventions to improve adherence to lipid‐lowering medication
1. Cardiovascular Diseases [prevention & control]; 2. Cholesterol [blood]; 3. Cholesterol, LDL [blood]; 4. Hypolipidemic Agents [*therapeutic use]; 5. *Medication Adherence [statistics & numerical data]; 6. Randomized Controlled Trials as Topic; 7. Reminder Systems;
MESH terms:
Oxygen therapy for acute myocardial infarction
1. *Oxygen Inhalation Therapy [adverse effects, mortality]; 2. Air; 3. Analgesics [therapeutic use]; 4. Cause of Death; 5. Intention to Treat Analysis; 6. Myocardial Infarction [mortality, pathology, *therapy]; 7. Pain Measurement [methods]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for short saphenous varicose veins
1. *Saphenous Vein [surgery]; 2. Catheter Ablation [*methods]; 3. Endovascular Procedures [*methods]; 4. Laser Therapy [*methods]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Recurrence; 8. Sclerotherapy [*methods]; 9. Ultrasonography, Interventional [methods]; 10. Varicose Veins [surgery, *therapy];
MESH terms:
Efficacy and safety of ablation for people with non‐paroxysmal atrial fibrillation
1. *Catheter Ablation [adverse effects]; 2. Anti‐Arrhythmia Agents [*therapeutic use]; 3. Atrial Fibrillation [*drug therapy, *surgery]; 4. Bradycardia [therapy]; 5. Electric Countershock [statistics & numerical data]; 6. Hospitalization [statistics & numerical data]; 7. Pacemaker, Artificial [statistics & numerical data]; 8. Randomized Controlled Trials as Topic; 9. Safety; 10. Treatment Outcome;
MESH terms:
Fibrates for primary prevention of cardiovascular disease events
1. *Primary Prevention [standards]; 2. Atorvastatin [therapeutic use]; 3. Bezafibrate [therapeutic use]; 4. Cardiovascular Diseases [mortality, *prevention & control]; 5. Clofibric Acid [analogs & derivatives, therapeutic use]; 6. Fenofibrate [therapeutic use]; 7. Gemfibrozil [therapeutic use]; 8. Hypolipidemic Agents [adverse effects, *therapeutic use]; 9. Myocardial Infarction [epidemiology, mortality]; 10. Simvastatin [therapeutic use]; 11. Stroke [epidemiology, mortality];
MESH terms:
Pharmacomechanical thrombectomy for iliofemoral deep vein thrombosis
1. *Catheterization, Peripheral; 2. *Endovascular Procedures; 3. *Femoral Vein; 4. *Iliac Vein; 5. Thrombectomy [*methods]; 6. Venous Thrombosis [*therapy];
MESH terms:
Pharmacological interventions other than botulinum toxin for spasticity after stroke
1. Baclofen [therapeutic use]; 2. Botulinum Toxins, Type A [therapeutic use]; 3. Clonidine [analogs & derivatives, therapeutic use]; 4. Diazepam [therapeutic use]; 5. Muscle Relaxants, Central [therapeutic use]; 6. Muscle Spasticity [*drug therapy]; 7. Randomized Controlled Trials as Topic; 8. Stroke [*complications]; 9. Tolperisone [therapeutic use];
MESH terms:
Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm
1. Anticoagulants [*therapeutic use]; 2. Heart Failure [*complications, mortality]; 3. Platelet Aggregation Inhibitors [*therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Thromboembolism [*drug therapy, etiology];
MESH terms:
Self management programmes for quality of life in people with stroke
1. *Health Behavior; 2. *Quality of Life; 3. *Stroke Rehabilitation; 4. Health Services Needs and Demand; 5. Independent Living; 6. Self Care [*methods]; 7. Self Efficacy;
MESH terms:
Venous cutdown versus the Seldinger technique for placement of totally implantable venous access ports
1. *Jugular Veins [diagnostic imaging]; 2. *Subclavian Vein [diagnostic imaging]; 3. *Vascular Access Devices [adverse effects]; 4. Arm [*blood supply]; 5. Catheter‐Related Infections; 6. Catheterization, Central Venous [adverse effects, *methods]; 7. Intention to Treat Analysis; 8. Pneumothorax [etiology]; 9. Randomized Controlled Trials as Topic; 10. Ultrasonography, Interventional [methods]; 11. Veins [diagnostic imaging]; 12. Venous Cutdown [adverse effects, *methods];
MESH terms:
Intravenous heparin during ruptured abdominal aortic aneurysmal repair
1. *Emergency Treatment; 2. Anticoagulants [*administration & dosage]; 3. Aortic Aneurysm, Abdominal [*surgery]; 4. Aortic Rupture [*surgery]; 5. Emergencies; 6. Heparin [*administration & dosage]; 7. Injections, Intravenous; 8. Intraoperative Period;
MESH terms:
Drug‐eluting balloon angioplasty versus uncoated balloon angioplasty for peripheral arterial disease of the lower limbs
1. Amputation, Surgical [statistics & numerical data]; 2. Angioplasty, Balloon [*methods, mortality]; 3. Drug‐Eluting Stents; 4. Femoral Artery; 5. Lower Extremity [*blood supply]; 6. Paclitaxel [*therapeutic use]; 7. Peripheral Arterial Disease [mortality, *therapy]; 8. Popliteal Artery; 9. Randomized Controlled Trials as Topic; 10. Tibial Arteries; 11. Time Factors; 12. Vascular Patency;
MESH terms:
Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy
1. Carbazoles [*therapeutic use]; 2. Cardiotonic Agents [adverse effects, *therapeutic use]; 3. Carvedilol; 4. Chagas Cardiomyopathy [*complications]; 5. Heart Failure [*drug therapy, etiology]; 6. Propanolamines [*therapeutic use]; 7. Quality of Life; 8. Randomized Controlled Trials as Topic; 9. Rosuvastatin Calcium [*therapeutic use]; 10. Survival Analysis;
MESH terms:
Sulodexide for treating venous leg ulcers
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Fibrinolytic Agents [adverse effects, *therapeutic use]; 3. Glycosaminoglycans [adverse effects, *therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Varicose Ulcer [*drug therapy];
MESH terms:
Routine invasive strategies versus selective invasive strategies for unstable angina and non‐ST elevation myocardial infarction in the stent era
1. Angina, Unstable [mortality, surgery, *therapy]; 2. Angioplasty, Balloon, Coronary [*adverse effects]; 3. Cause of Death; 4. Coronary Angiography; 5. Coronary Artery Disease [therapy]; 6. Myocardial Infarction [mortality, surgery, *therapy]; 7. Platelet Glycoprotein GPIIb‐IIIa Complex [antagonists & inhibitors]; 8. Randomized Controlled Trials as Topic; 9. Sex Factors; 10. Stents;
MESH terms:
Implantable loop recorder versus conventional diagnostic workup for unexplained recurrent syncope
1. *Electrodes, Implanted; 2. Electrocardiography [*instrumentation]; 3. Quality of Life; 4. Randomized Controlled Trials as Topic; 5. Recurrence; 6. Syncope [*diagnosis, etiology, mortality];
MESH terms:
Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
1. Anticoagulants [*therapeutic use]; 2. Arthroplasty, Replacement, Hip [*adverse effects]; 3. Arthroplasty, Replacement, Knee [*adverse effects]; 4. Hemorrhage [chemically induced]; 5. Heparin [*therapeutic use]; 6. Hip Fractures [*surgery]; 7. Randomized Controlled Trials as Topic; 8. Venous Thromboembolism [*prevention & control]; 9. Vitamin K [*antagonists & inhibitors];
MESH terms:
Pre‐hospital versus in‐hospital initiation of cooling for survival and neuroprotection after out‐of‐hospital cardiac arrest
1. *Death, Sudden, Cardiac; 2. *Neuroprotection; 3. Emergency Medical Services [*methods]; 4. Hypothermia, Induced [adverse effects, *methods]; 5. Hypoxia, Brain [*prevention & control]; 6. Out‐of‐Hospital Cardiac Arrest [*mortality, *therapy]; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Risk;
MESH terms:
Blood pressure lowering efficacy of beta‐1 selective beta blockers for primary hypertension
1. Adrenergic beta‐Antagonists [administration & dosage, *therapeutic use]; 2. Antihypertensive Agents [administration & dosage, *therapeutic use]; 3. Blood Pressure [drug effects]; 4. Diastole [drug effects]; 5. Essential Hypertension; 6. Heart Rate [drug effects]; 7. Hypertension [*drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Systole [drug effects];
MESH terms:
Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals
1. Antihypertensive Agents [*therapeutic use]; 2. Death, Sudden, Cardiac [*prevention & control]; 3. Hypertension [complications, *drug therapy]; 4. Myocardial Infarction [*prevention & control]; 5. Randomized Controlled Trials as Topic;
MESH terms:
Interventions for helping people adhere to compression treatments for venous leg ulceration
1. *Patient Compliance; 2. *Self‐Help Groups; 3. Behavior Therapy; 4. Chronic Disease; 5. Compression Bandages; 6. Counseling [methods]; 7. Exercise; 8. Goals; 9. Interpersonal Relations; 10. Practice Patterns, Nurses'; 11. Randomized Controlled Trials as Topic; 12. Recurrence; 13. Self Care; 14. Varicose Ulcer [*therapy]; 15. Wound Healing;
MESH terms:
Calcium channel blockers for primary Raynaud's phenomenon
1. Calcium Channel Blockers [*therapeutic use]; 2. Nicardipine [therapeutic use]; 3. Nifedipine [therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Raynaud Disease [*drug therapy];
MESH terms:
Sexual counselling for sexual problems in patients with cardiovascular disease
1. *Sex Counseling; 2. Cardiac Rehabilitation; 3. Cardiovascular Diseases [*complications]; 4. Coronary Artery Bypass; 5. Myocardial Infarction [complications, rehabilitation]; 6. Patient Satisfaction; 7. Randomized Controlled Trials as Topic; 8. Sexual Dysfunction, Physiological [psychology, *rehabilitation]; 9. Sexual Partners;
MESH terms:
Oral aspirin for treating venous leg ulcers
1. Administration, Oral; 2. Anti‐Inflammatory Agents, Non‐Steroidal [*administration & dosage]; 3. Aspirin [*administration & dosage]; 4. Compression Bandages; 5. Randomized Controlled Trials as Topic; 6. Varicose Ulcer [*drug therapy]; 7. Wound Healing [*drug effects];
MESH terms:
Biphasic versus monophasic waveforms for transthoracic defibrillation in out‐of‐hospital cardiac arrest
1. Blood Circulation; 2. Defibrillators; 3. Electric Countershock [*methods, mortality]; 4. Out-of-Hospital Cardiac Arrest [mortality, *therapy]; 5. Randomized Controlled Trials as Topic; 6. Time Factors; 7. Ventricular Fibrillation [*therapy];
MESH terms:
Systematic versus opportunistic risk assessment for the primary prevention of cardiovascular disease
1. Cardiovascular Diseases [mortality, *prevention & control]; 2. Cholesterol [blood]; 3. Primary Prevention [*methods]; 4. Randomized Controlled Trials as Topic; 5. Risk Assessment [methods]; 6. Risk Factors; 7. Stroke [mortality];
MESH terms:
Warfarin initiation nomograms for venous thromboembolism
1. *International Normalized Ratio; 2. *Nomograms; 3. Anticoagulants [*administration & dosage]; 4. Pulmonary Embolism [drug therapy]; 5. Time Factors; 6. Venous Thromboembolism [*drug therapy]; 7. Venous Thrombosis [drug therapy]; 8. Warfarin [*administration & dosage];
MESH terms:
Perioperative angiotensin‐converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults
1. *Anesthesia, General; 2. Angiotensin II Type 1 Receptor Blockers [*therapeutic use]; 3. Angiotensin‐Converting Enzyme Inhibitors [*therapeutic use]; 4. Cardiac Surgical Procedures [adverse effects, *mortality]; 5. Cause of Death; 6. Cerebrovascular Disorders [prevention & control]; 7. Heart Failure [prevention & control]; 8. Hypertension [*drug therapy]; 9. Hypotension [prevention & control]; 10. Length of Stay; 11. Myocardial Infarction [prevention & control]; 12. Perioperative Care [*methods, mortality]; 13. Randomized Controlled Trials as Topic; 14. Renal Insufficiency [prevention & control]; 15. Surgical Procedures, Operative [mortality]; 16. Vascular Surgical Procedures [adverse effects, *mortality];
MESH terms:
Colchicine for prevention of cardiovascular events
1. Anti-Inflammatory Agents [adverse effects, *therapeutic use]; 2. Cardiovascular Diseases [mortality, *prevention & control]; 3. Cause of Death; 4. Colchicine [adverse effects, *therapeutic use]; 5. Heart Failure [prevention & control]; 6. Myocardial Infarction [mortality, prevention & control]; 7. Randomized Controlled Trials as Topic; 8. Risk; 9. Stroke [mortality, prevention & control];
MESH terms:
A 'test and treat' strategy for elevated wound protease activity for healing in venous leg ulcers
1. *Wound Healing; 2. Clinical Enzyme Tests; 3. Peptide Hydrolases [*analysis]; 4. Varicose Ulcer [*enzymology, *therapy];
MESH terms:
Internet‐based interventions for the secondary prevention of coronary heart disease
1. *Internet; 2. *Life Style; 3. Coronary Artery Disease [*prevention & control, rehabilitation]; 4. Diet; 5. Exercise; 6. Quality of Life; 7. Randomized Controlled Trials as Topic; 8. Risk Reduction Behavior; 9. Secondary Prevention [*methods];
MESH terms:
Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction
1. *Practice Patterns, Nurses'; 2. Adrenergic beta‐Antagonists [*administration & dosage]; 3. Angiotensin Receptor Antagonists [*administration & dosage]; 4. Angiotensin‐Converting Enzyme Inhibitors [*administration & dosage]; 5. Cause of Death; 6. Dose‐Response Relationship, Drug; 7. Drug Monitoring [*nursing]; 8. Heart Failure [*drug therapy, mortality, *nursing, physiopathology]; 9. Hospitalization [statistics & numerical data]; 10. Randomized Controlled Trials as Topic; 11. Stroke Volume; 12. Time Factors;
MESH terms:
Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death
1. Amiodarone [*therapeutic use]; 2. Anti-Arrhythmia Agents [*therapeutic use]; 3. Cause of Death; 4. Death, Sudden, Cardiac [*prevention & control]; 5. *Primary Prevention; 6. Randomized Controlled Trials as Topic; 7. *Secondary Prevention; 8. Vasodilator Agents [therapeutic use];
MESH terms:
Aminophylline for bradyasystolic cardiac arrest in adults
1. Aminophylline [*therapeutic use]; 2. Bradycardia [complications]; 3. Cardiotonic Agents [*therapeutic use]; 4. Injections, Intravenous; 5. Out-of-Hospital Cardiac Arrest [*drug therapy, etiology, mortality]; 6. Randomized Controlled Trials as Topic; 7. Survival Analysis;
MESH terms:
Structured telephone support or non‐invasive telemonitoring for patients with heart failure
1. Chronic Disease; 2. Heart Failure [mortality, *therapy]; 3. Hospitalization [statistics & numerical data]; 4. Length of Stay [statistics & numerical data]; 5. Quality of Life; 6. Randomized Controlled Trials as Topic; 7. Telemetry [*methods]; 8. *Telephone;
MESH terms:
Fibrates for secondary prevention of cardiovascular disease and stroke
1. Anticholesteremic Agents [*therapeutic use]; 2. Bezafibrate [therapeutic use]; 3. Cardiovascular Diseases [mortality, *prevention & control]; 4. Cause of Death; 5. Cholesterol, HDL; 6. Clofibrate [therapeutic use]; 7. Coronary Disease [mortality]; 8. Fenofibrate [therapeutic use]; 9. Fibric Acids [adverse effects, *therapeutic use]; 10. Gemfibrozil [therapeutic use]; 11. Hypertriglyceridemia [drug therapy]; 12. Myocardial Infarction [mortality, prevention & control]; 13. Randomized Controlled Trials as Topic; 14. Secondary Prevention [*methods]; 15. Stroke [mortality, prevention & control];
MESH terms:
Implantable defibrillators versus medical therapy for cardiac channelopathies
1. *Defibrillators, Implantable [adverse effects]; 2. Adrenergic beta‐Antagonists [adverse effects, *therapeutic use]; 3. Brugada Syndrome [etiology, *therapy]; 4. Channelopathies [complications, *therapy]; 5. Death, Sudden, Cardiac [etiology, *prevention & control]; 6. Heart Diseases [therapy]; 7. Randomized Controlled Trials as Topic; 8. Secondary Prevention [*methods];
MESH terms:
Stent graft types for endovascular repair of thoracic aortic aneurysms
1. Aortic Aneurysm, Thoracic [*surgery]; 2. Endovascular Procedures [*methods]; 3. Stents [*classification];
MESH terms:
Debridement for venous leg ulcers
1. Bandages, Hydrocolloid; 2. Borates [therapeutic use]; 3. Debridement [*methods]; 4. Hydrogel, Polyethylene Glycol Dimethacrylate [therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Sodium Hypochlorite [therapeutic use]; 7. Varicose Ulcer [*therapy]; 8. Wound Healing;
MESH terms:
Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
1. *Septal Occluder Device; 2. Anticoagulants [*therapeutic use]; 3. Fibrinolytic Agents [therapeutic use]; 4. Foramen Ovale, Patent [complications, drug therapy, *therapy]; 5. Ischemic Attack, Transient [etiology, *prevention & control]; 6. Platelet Aggregation Inhibitors [therapeutic use]; 7. Randomized Controlled Trials as Topic; 8. Recurrence; 9. Risk Assessment; 10. Secondary Prevention [*methods]; 11. Stroke [etiology, *prevention & control];
MESH terms:
Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension
1. Adrenergic alpha‐1 Receptor Antagonists [*therapeutic use]; 2. Adrenergic beta‐Antagonists [*therapeutic use]; 3. Antihypertensive Agents [*therapeutic use]; 4. Blood Pressure [*drug effects]; 5. Carbazoles [therapeutic use]; 6. Carvedilol; 7. Essential Hypertension; 8. Heart Rate [drug effects]; 9. Hypertension [*drug therapy]; 10. Labetalol [therapeutic use]; 11. Propanolamines [therapeutic use]; 12. Randomized Controlled Trials as Topic; 13. Withholding Treatment;
MESH terms:
Prophylactic lidocaine for myocardial infarction
1. Anti-Arrhythmia Agents [*therapeutic use]; 2. Arrhythmias, Cardiac [mortality, *prevention & control]; 3. Bradycardia [mortality, prevention & control]; 4. Lidocaine [*therapeutic use]; 5. Myocardial Infarction [*complications, mortality]; 6. Randomized Controlled Trials as Topic; 7. Ventricular Fibrillation [mortality, prevention & control];
MESH terms:
Buflomedil for acute ischaemic stroke
1. China; 2. Platelet Aggregation Inhibitors [*therapeutic use]; 3. Pyrrolidines [*therapeutic use]; 4. Randomized Controlled Trials as Topic; 5. Stroke [*drug therapy, mortality];
MESH terms:
Negative pressure wound therapy for treating leg ulcers
1. *Negative‐Pressure Wound Therapy; 2. Leg Ulcer [*therapy]; 3. Randomized Controlled Trials as Topic;
MESH terms:
Fresh frozen plasma for cardiovascular surgery
1. Blood Loss, Surgical [prevention & control]; 2. Cardiovascular Surgical Procedures [*mortality]; 3. Elective Surgical Procedures [mortality]; 4. Erythrocyte Transfusion; 5. *Hemostasis, Surgical; 6. *Plasma; 7. Randomized Controlled Trials as Topic; 8. Risk Assessment;
MESH terms:
Psychosocial interventions for smoking cessation in patients with coronary heart disease
1. *Coronary Disease; 2. *Myocardial Infarction; 3. Distance Counseling; 4. Motivation; 5. Obesity [therapy]; 6. Randomized Controlled Trials as Topic; 7. Risk Factors; 8. Sedentary Behavior; 9. Self Care; 10. Smoking Cessation [*methods, psychology]; 11. Telephone; 12. Time Factors;
MESH terms:
Interventions for post‐stroke fatigue
1. Antidepressive Agents [therapeutic use]; 2. Drugs, Chinese Herbal [therapeutic use]; 3. Fatigue [etiology, *therapy]; 4. Mindfulness [methods]; 5. Randomized Controlled Trials as Topic; 6. Stress, Psychological [prevention & control]; 7. Stroke [*complications, psychology];
MESH terms:
Psychological interventions for symptomatic management of non‐specific chest pain in patients with normal coronary anatomy
1. Behavior Therapy; 2. Chest Pain [*psychology, therapy]; 3. Cognitive Behavioral Therapy [*methods]; 4. Coronary Vessels [*anatomy & histology]; 5. Hypnosis; 6. Microvascular Angina [psychology, therapy]; 7. Psychotherapy [methods]; 8. Randomized Controlled Trials as Topic; 9. Recurrence; 10. Treatment Outcome;
MESH terms:
Primary prophylaxis for venous thromboembolism in patients undergoing cardiac or thoracic surgery
1. Anticoagulants [therapeutic use]; 2. Cardiac Surgical Procedures [*adverse effects, statistics & numerical data]; 3. Hemorrhage [chemically induced]; 4. Heparin [therapeutic use]; 5. Primary Prevention [*methods]; 6. Randomized Controlled Trials as Topic; 7. Stockings, Compression; 8. Thoracic Surgical Procedures [*adverse effects, statistics & numerical data]; 9. Venous Thromboembolism [epidemiology, *prevention & control];
MESH terms:
Motivational interviewing for improving recovery after stroke
1. *Activities of Daily Living [psychology]; 2. *Motivation; 3. *Motivational Interviewing; 4. *Stroke Rehabilitation; 5. Randomized Controlled Trials as Topic; 6. Recovery of Function; 7. Stroke [psychology];
MESH terms:
Anti‐inflammatory treatment for carditis in acute rheumatic fever
1. Anti‐Inflammatory Agents [*therapeutic use]; 2. Aspirin [therapeutic use]; 3. Immunoglobulins, Intravenous [therapeutic use]; 4. Myocarditis [*drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Rheumatic Heart Disease [*drug therapy]; 7. Steroids [therapeutic use];
MESH terms:
Blood pressure‐lowering efficacy of loop diuretics for primary hypertension
1. Antihypertensive Agents [*administration & dosage, adverse effects]; 2. Blood Pressure [*drug effects]; 3. Dose‐Response Relationship, Drug; 4. Furosemide [administration & dosage, adverse effects]; 5. Hypertension [*drug therapy]; 6. Indans [administration & dosage, adverse effects]; 7. Pyridines [administration & dosage, adverse effects]; 8. Randomized Controlled Trials as Topic; 9. Sodium Potassium Chloride Symporter Inhibitors [*administration & dosage, adverse effects]; 10. Sulfonamides [administration & dosage, adverse effects]; 11. Thiazoles [administration & dosage, adverse effects];
MESH terms:
Adenosine and verapamil for no‐reflow during primary percutaneous coronary intervention in people with acute myocardial infarction
1. *Percutaneous Coronary Intervention; 2. Adenosine [adverse effects, *therapeutic use]; 3. Cause of Death; 4. Myocardial Infarction [mortality, *surgery]; 5. No‐Reflow Phenomenon [*drug therapy, mortality]; 6. Randomized Controlled Trials as Topic; 7. Vasodilator Agents [adverse effects, *therapeutic use]; 8. Verapamil [*therapeutic use];
MESH terms:
Influenza vaccines for preventing cardiovascular disease
1. Coronary Disease [mortality, *prevention & control]; 2. Influenza Vaccines [*therapeutic use]; 3. Influenza, Human [prevention & control]; 4. Primary Prevention; 5. Randomized Controlled Trials as Topic; 6. Secondary Prevention;
MESH terms:
Intra‐aortic balloon pump counterpulsation (IABP) for myocardial infarction complicated by cardiogenic shock
1. Assisted Circulation [instrumentation, methods]; 2. Intra-Aortic Balloon Pumping [*methods]; 3. Myocardial Infarction [*complications]; 4. Randomized Controlled Trials as Topic; 5. Shock, Cardiogenic [etiology, *therapy];
MESH terms:
Anaesthetic and sedative agents used for electrical cardioversion
1. Anesthetics [*administration & dosage, adverse effects]; 2. Apnea [chemically induced]; 3. Diazepam [administration & dosage, adverse effects]; 4. Electric Countershock [adverse effects, *methods]; 5. Etomidate [administration & dosage, adverse effects]; 6. Fentanyl [administration & dosage, adverse effects]; 7. Hypnotics and Sedatives [*administration & dosage, adverse effects]; 8. Hypotension [chemically induced]; 9. Mental Recall; 10. Methyl Ethers [administration & dosage, adverse effects]; 11. Midazolam [administration & dosage, adverse effects]; 12. Piperidines [administration & dosage, adverse effects]; 13. Propofol [administration & dosage, adverse effects]; 14. Randomized Controlled Trials as Topic; 15. Remifentanil; 16. Sevoflurane; 17. Thiopental [administration & dosage, adverse effects];
MESH terms:
Interventions for improving community ambulation in individuals with stroke
1. *Stroke Rehabilitation; 2. Activities of Daily Living; 3. Environment Design; 4. Gait [physiology]; 5. Randomized Controlled Trials as Topic; 6. Residence Characteristics; 7. Self Efficacy; 8. Time Factors; 9. Walking [*physiology];
MESH terms:
Atorvastatin for lowering lipids
1. Atorvastatin; 2. Cholesterol [*blood]; 3. Cholesterol, HDL [blood]; 4. Cholesterol, LDL [blood]; 5. Controlled Before‐After Studies; 6. Dose‐Response Relationship, Drug; 7. Heptanoic Acids [*administration & dosage]; 8. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [*administration & dosage]; 9. Hyperlipidemias [blood, drug therapy]; 10. Lipids [blood]; 11. Pyrroles [*administration & dosage]; 12. Randomized Controlled Trials as Topic; 13. Sex Factors; 14. Triglycerides [blood];
MESH terms:
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass
1. Acute Kidney Injury [*prevention & control, therapy]; 2. Atorvastatin; 3. Cardiac Surgical Procedures; 4. Cardiopulmonary Bypass [*adverse effects]; 5. Coronary Artery Bypass [*adverse effects]; 6. Creatinine [blood]; 7. Fluorobenzenes [therapeutic use]; 8. Heptanoic Acids [*therapeutic use]; 9. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [*therapeutic use]; 10. Length of Stay; 11. Pyrimidines [therapeutic use]; 12. Pyrroles [*therapeutic use]; 13. Randomized Controlled Trials as Topic; 14. Renal Replacement Therapy; 15. Rosuvastatin Calcium; 16. Simvastatin [therapeutic use]; 17. Sulfonamides [therapeutic use];
MESH terms:
Transmyocardial laser revascularization versus medical therapy for refractory angina
1. Angina Pectoris [mortality, *therapy]; 2. Laser Therapy [adverse effects, *methods, mortality]; 3. Myocardial Revascularization [adverse effects, *methods, mortality]; 4. Randomized Controlled Trials as Topic; 5. Thoracotomy;
MESH terms:
Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery
1. Anastomosis, Surgical [adverse effects, methods]; 2. Anticoagulants [therapeutic use]; 3. Arteriosclerosis [surgery]; 4. Aspirin [therapeutic use]; 5. Dipyridamole [therapeutic use]; 6. Graft Occlusion, Vascular [etiology, *prevention & control]; 7. Intermittent Claudication [surgery]; 8. Peripheral Vascular Diseases [*surgery]; 9. Platelet Aggregation Inhibitors [*therapeutic use]; 10. Randomized Controlled Trials as Topic; 11. Thrombosis [*prevention & control]; 12. Vascular Patency;
MESH terms:
Effectiveness of the Valsalva Manoeuvre for reversion of supraventricular tachycardia
1. Randomized Controlled Trials as Topic; 2. Tachycardia, Supraventricular [*therapy]; 3. Treatment Outcome; 4. Valsalva Maneuver [*physiology];
MESH terms:
Beta‐adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery
1. Administration, Oral; 2. Adrenergic beta‐Antagonists [administration & dosage, *therapeutic use]; 3. Cardiovascular Diseases [*prevention & control]; 4. Cause of Death; 5. Injections, Intravenous; 6. Metoprolol [administration & dosage, *therapeutic use]; 7. Postoperative Complications [mortality, *prevention & control]; 8. Randomized Controlled Trials as Topic; 9. Risk Reduction Behavior; 10. Vascular Surgical Procedures [*adverse effects];
MESH terms:
Statins for primary prevention of venous thromboembolism
1. Fluorobenzenes [adverse effects, *therapeutic use]; 2. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [adverse effects, *therapeutic use]; 3. Myocardial Infarction [prevention & control]; 4. Pyrimidines [adverse effects, *therapeutic use]; 5. Randomized Controlled Trials as Topic; 6. Rosuvastatin Calcium; 7. Stroke [prevention & control]; 8. Sulfonamides [adverse effects, *therapeutic use]; 9. Venous Thromboembolism [*prevention & control]; 10. Venous Thrombosis [prevention & control];
MESH terms:
Biologics, colchicine, corticosteroids, immunosuppressants and interferon‐alpha for Neuro‐Behçet's Syndrome
1. Adrenal Cortex Hormones [therapeutic use]; 2. Behcet Syndrome [complications, *drug therapy]; 3. Biological Products [therapeutic use]; 4. Central Nervous System Diseases [*drug therapy, etiology]; 5. Colchicine [therapeutic use]; 6. Immunosuppressive Agents [therapeutic use]; 7. Interferon‐alpha [therapeutic use];
MESH terms:
Balloon angioplasty, with and without stenting, versus medical therapy for hypertensive patients with renal artery stenosis
1. *Angioplasty, Balloon; 2. *Stents; 3. Antihypertensive Agents [*therapeutic use]; 4. Combined Modality Therapy [methods]; 5. Hypertension [*therapy]; 6. Randomized Controlled Trials as Topic; 7. Renal Artery Obstruction [*therapy];
MESH terms:
Blood pressure lowering efficacy of partial agonist beta blocker monotherapy for primary hypertension
1. Adrenergic beta‐1 Receptor Antagonists [*therapeutic use]; 2. Antihypertensive Agents [*therapeutic use]; 3. Blood Pressure [*drug effects]; 4. Dose‐Response Relationship, Drug; 5. Essential Hypertension; 6. Heart Rate [drug effects]; 7. Hypertension [*drug therapy]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Rosuvastatin for lowering lipids
1. Cardiovascular Diseases [blood]; 2. Cholesterol [blood]; 3. Cholesterol, HDL [blood]; 4. Cholesterol, LDL [blood]; 5. Dose‐Response Relationship, Drug; 6. Drug Administration Schedule; 7. Fluorobenzenes [*administration & dosage]; 8. Hydroxymethylglutaryl‐CoA Reductase Inhibitors [*administration & dosage]; 9. Hyperlipidemias [blood, *drug therapy]; 10. Lipids [*blood]; 11. Pyrimidines [*administration & dosage]; 12. Randomized Controlled Trials as Topic; 13. Rosuvastatin Calcium; 14. Sulfonamides [*administration & dosage]; 15. Triglycerides [blood];
MESH terms:
Interventions for deliberately altering blood pressure in acute stroke
1. Acute Disease; 2. Blood Pressure [*drug effects]; 3. Calcium Channel Blockers [*therapeutic use]; 4. Hypertension [drug therapy]; 5. Randomized Controlled Trials as Topic; 6. Risk; 7. Stroke [physiopathology, *prevention & control]; 8. Time‐to‐Treatment [statistics & numerical data]; 9. Vasodilator Agents [*therapeutic use];
MESH terms:
Cardiopulmonary resuscitation (CPR) plus delayed defibrillation versus immediate defibrillation for out‐of‐hospital cardiac arrest
1. Cardiopulmonary Resuscitation [*methods, mortality]; 2. Combined Modality Therapy [methods, mortality]; 3. Electric Countershock [*methods, mortality]; 4. Out‐of‐Hospital Cardiac Arrest [mortality, *therapy]; 5. Randomized Controlled Trials as Topic; 6. Time Factors;
MESH terms:
Pre‐hospital versus in‐hospital thrombolysis for ST‐elevation myocardial infarction
1. *Emergency Medical Services; 2. *Thrombolytic Therapy [adverse effects, mortality]; 3. Fibrinolytic Agents [*administration & dosage, adverse effects]; 4. Hemorrhage [chemically induced]; 5. Myocardial Infarction [*drug therapy, mortality]; 6. Randomized Controlled Trials as Topic; 7. Time‐to‐Treatment;
MESH terms:
Time course for blood pressure lowering of dihydropyridine calcium channel blockers
1. Antihypertensive Agents [administration & dosage, *therapeutic use]; 2. Blood Pressure [*drug effects, physiology]; 3. Calcium Channel Blockers [*therapeutic use]; 4. Circadian Rhythm; 5. Dihydropyridines [administration & dosage, *therapeutic use]; 6. Drug Administration Schedule; 7. Hypertension [*drug therapy]; 8. Randomized Controlled Trials as Topic; 9. Time Factors;
MESH terms:
Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension
1. Angiotensin Receptor Antagonists [adverse effects, *therapeutic use]; 2. Angiotensin‐Converting Enzyme Inhibitors [adverse effects, *therapeutic use]; 3. Antihypertensive Agents [adverse effects, *therapeutic use]; 4. Essential Hypertension; 5. Heart Diseases [mortality]; 6. Hypertension [complications, *drug therapy, mortality]; 7. Hypotension; 8. Randomized Controlled Trials as Topic; 9. Stroke [mortality];
MESH terms:
Exercise for people with high cardiovascular risk
1. *Exercise; 2. Blood Pressure; 3. Body Mass Index; 4. Cardiovascular Diseases [blood, *prevention & control]; 5. Cholesterol, HDL [blood]; 6. Cholesterol, LDL [blood]; 7. Exercise Tolerance; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Risk Factors; 11. Smoking;
MESH terms:
Heparin versus placebo for non‐ST elevation acute coronary syndromes
1. Acute Coronary Syndrome [*drug therapy, mortality]; 2. Angina, Unstable [drug therapy]; 3. Anticoagulants [adverse effects, *therapeutic use]; 4. Heparin [adverse effects, *therapeutic use]; 5. Heparin, Low-Molecular-Weight [adverse effects, therapeutic use]; 6. Myocardial Infarction [prevention & control]; 7. Placebos [therapeutic use]; 8. Randomized Controlled Trials as Topic;
MESH terms:
Angioplasty versus bare metal stenting for superficial femoral artery lesions
1. *Femoral Artery; 2. *Stents; 3. Angioplasty, Balloon [*methods]; 4. Anticoagulants [therapeutic use]; 5. Combined Modality Therapy [methods]; 6. Intermittent Claudication [therapy]; 7. Peripheral Vascular Diseases [*therapy]; 8. Quality of Life; 9. Randomized Controlled Trials as Topic; 10. Vascular Patency;
MESH terms:
Anticoagulation therapy versus placebo for pulmonary hypertension
1. Anticoagulants [adverse effects, *therapeutic use]; 2. Hypertension, Pulmonary [*drug therapy]; 3. International Normalized Ratio; 4. Placebos [therapeutic use];
MESH terms:
Blood pressure‐lowering efficacy of monotherapy with thiazide diuretics for primary hypertension
1. Antihypertensive Agents [*administration & dosage, adverse effects]; 2. Blood Pressure [drug effects]; 3. Chlorthalidone [administration & dosage, adverse effects]; 4. Essential Hypertension; 5. Hydrochlorothiazide [administration & dosage, adverse effects]; 6. Hypertension [*drug therapy]; 7. Indapamide [administration & dosage, adverse effects]; 8. Randomized Controlled Trials as Topic; 9. Sodium Chloride Symporter Inhibitors [*administration & dosage, adverse effects];
MESH terms:
Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection
1. Chagas Cardiomyopathy [prevention & control]; 2. Chagas Disease [*drug therapy]; 3. Chronic Disease; 4. Observational Studies as Topic; 5. Randomized Controlled Trials as Topic; 6. Trypanocidal Agents [*therapeutic use]; 7. Trypanosoma cruzi;
MESH terms:
Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication
1. Administration, Oral; 2. Ankle Brachial Index; 3. Anticoagulants [adverse effects, *therapeutic use]; 4. Hemorrhage [chemically induced]; 5. Heparin [adverse effects, therapeutic use]; 6. Heparin, Low‐Molecular‐Weight [adverse effects, therapeutic use]; 7. Intermittent Claudication [*drug therapy]; 8. Prospective Studies; 9. Randomized Controlled Trials as Topic;
MESH terms:
Type of incision for below knee amputation
1. Amputation, Surgical [*methods]; 2. Diabetic Foot [*surgery]; 3. Gangrene [complications, surgery]; 4. Ischemia [*surgery]; 5. Leg [*blood supply]; 6. Randomized Controlled Trials as Topic; 7. Reoperation; 8. Surgical Flaps; 9. Treatment Outcome; 10. Wound Healing;
MESH terms:
Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non‐valvular atrial fibrillation
1. Amidines [therapeutic use]; 2. Antithrombins [adverse effects, *therapeutic use]; 3. Atrial Fibrillation [*complications]; 4. Azetidines [adverse effects, therapeutic use]; 5. Benzimidazoles [therapeutic use]; 6. Benzylamines [adverse effects, therapeutic use]; 7. Dabigatran; 8. Drug Administration Schedule; 9. Embolism [etiology, *prevention & control]; 10. Randomized Controlled Trials as Topic; 11. Safety‐Based Drug Withdrawals; 12. Stroke [etiology, *prevention & control]; 13. Vitamin K [*antagonists & inhibitors]; 14. Warfarin [therapeutic use]; 15. beta‐Alanine [analogs & derivatives, therapeutic use];
MESH terms:
Glycoprotein IIb‐IIIa inhibitors for acute ischaemic stroke
1. Abciximab; 2. Antibodies, Monoclonal [adverse effects, *therapeutic use]; 3. Aspirin [adverse effects, *therapeutic use]; 4. Brain Ischemia [drug therapy]; 5. Immunoglobulin Fab Fragments [adverse effects, *therapeutic use]; 6. Intracranial Hemorrhages [chemically induced]; 7. Platelet Aggregation Inhibitors [adverse effects, *therapeutic use]; 8. Platelet Glycoprotein GPIIb-IIIa Complex [*antagonists & inhibitors]; 9. Randomized Controlled Trials as Topic; 10. Stroke [*drug therapy]; 11. Tirofiban; 12. Tyrosine [adverse effects, *analogs & derivatives, therapeutic use];
MESH terms:
Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis
1. Antibiotic Prophylaxis [adverse effects, *methods]; 2. Antitubercular Agents [adverse effects, *therapeutic use]; 3. Chemical and Drug Induced Liver Injury [etiology]; 4. Hepatitis B [complications]; 5. Hepatitis C [complications]; 6. Immunosuppression Therapy [adverse effects]; 7. Isoniazid [adverse effects, *therapeutic use]; 8. Kidney Transplantation [*adverse effects]; 9. Tuberculosis [*prevention & control];
MESH terms:
Combined oral contraceptives: venous thrombosis
1. Androstenes [adverse effects]; 2. Contraceptives, Oral, Combined [*adverse effects]; 3. Cyproterone [adverse effects]; 4. Desogestrel [adverse effects]; 5. Ethinyl Estradiol [adverse effects]; 6. Levonorgestrel [adverse effects]; 7. Norpregnenes [adverse effects]; 8. Pulmonary Embolism [*chemically induced]; 9. Randomized Controlled Trials as Topic; 10. Venous Thrombosis [*chemically induced];